Perthera Report Pancreatic

AVAILABLE NOW: The Pethera Report® Pancreatic version | New Customers: Order your first report

World’s First AI Predictor Boosts Accuracy of Frontline Pancreatic Chemotherapy Selection

We designed the Perthera Report® Pancreatic as a game-changing precision oncology tool specifically for pancreatic cancer patients.

The report features PDACai, Perthera’s newly announced frontline chemotherapy predictor, which provides ranked therapy recommendations for the two most common pancreatic cancer treatments: FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GA).

Predict frontline chemotherapy effectiveness before treatment begins

Download Sample Order Now

Match patients to the cancer therapy that delivers the best outcome

The Perthera Report Pancreatic provides ranked, personalized therapy options tailored to your patient’s unique tumor profile, multi-omics data, and medical history. The report includes PDACai, a validated AI signature designed to predict front-line chemotherapy effectiveness for newly diagnosed patients.

“The Perthera Report Pancreatic is revolutionizing treatment planning, giving doctors a level of confidence and accuracy never before possible.”

PhD, Chief Science Officer and Co-Founder of Perthera

600+ hospitals have ordered the Perthera Report

Johns Hopkins

New York Presbyterian Hospital

Sharp Memorial Hospital

Baylor Scott & White

City of Hope

Jefferson

Mayo Clinic

MD Anderson Cancer Center

Seattle Cancer Care Alliance

University of Vermont Health Network

UVA Health

Virginia Mason Franciscan Health Logo

“Empowering oncologists with data-driven predictions to choose amongst standard of care therapy options can significantly improve outcomes for patients with pancreatic cancer”

Anna Berkenblit, MD, MMSc, Chief Scientific & Medical Officer, PanCAN

A peer-reviewed study published in The Lancet Oncology shows that patients experience up to a 2.4-fold improvement in progression-free survival when their provider follows Perthera Report ranked options. PDACai builds on this success, further advancing personalized treatment strategies for better pancreatic patient outcomes.

Learn how patient outcomes improve by up to 2.4-fold with Perthera

Transform how you treat pancreatic cancer patients

01

Gain Precision Insights for Better Pancreatic Cancer Care

The Perthera Report Pancreatic version provides the tools, insights, and expert support you need to deliver precision treatments that improve outcomes and quality of life. For frontline patients, the report includes PDACai, a clinically validated signature that eliminates uncertainty in chemotherapy selection, a breakthrough that could save crucial time in treating patients.

02

Collaborate with leading experts to get their treatment insights

Obtain input from top oncology specialists through our virtual Molecular Tumor Board, ensuring decisions are informed by cutting-edge expertise.

03

Leverage Clear, Actionable Insights from NGS Testing

The Perthera Report Pancreatic version transforms overwhelming NGS testing data into concise, actionable insights, helping you focus on what matters most—patient care. Now with PRPv’s predictive intelligence, you can make precise, data driven, personalized treatment decisions from day one.

04

Stay ahead in a rapidly evolving field

With new therapies, research, and guidelines emerging daily, staying ahead of the curve is challenging. The Perthera Report Pancreatic version keeps you informed with ranked options grounded on the latest evidence, guidelines, and expert opinions.

05

Make confident, personalized decisions

Receive ranked, evidence-based therapy options tailored to your patient’s unique tumor profile and medical history. With clear rationales and references to support, confident decision making. You have access to an AI-powered tool that provides a data-driven likelihood of response prediction for frontline chemotherapy treatment of PDAC, giving you a level of confidence and accuracy never before possible.